Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by davgroon Mar 09, 2023 11:34am
106 Views
Post# 35328222

RE:Total amount of insider buying $38,000

RE:Total amount of insider buying $38,000I must clarify the Dumpster's previous post for any ATE investors or those considering buying ATE stock.

There was NO insider buying of ATE stock as the Dumpster has erroneously stated.  The SEDI filings for ATE show the vesting of RSUs by management and the subsequent transfer of those shares to the owner.  This is a standard compensation practice for a publicly traded company.

Since the vested RSUs have been transferred to insiders they must be publicly reported.  The price listed is the FMV (Fair Market Value) assigned once they have vested.

These transactions in no way show an insiders commitment to the company as it is merely another form of executive compensation unlike a "Public Market Buy" which is a true Insider Purchase of stock.

Don't be misled by the Dumpster's misinformation, he is just trying to pump up the stock so he can flip you his shares.


Duster340 wrote: since jan/11
name                      # of shares                    price          total          
R Flower                    13,333                        @59          $7,866
Y. Wu                         13,333                        @59          $7,866
R. Hoffman                11,667                        @59          $6,884
J. Mcnealy                 11,667                        @59          $6,884
J. Stauffer                  16,667                        @51          $8,500
                                                                     TOTAL       $38,000  Canadian


i have slowly been adding more over the last 2 weeks. i think a lot of people are sleeping on this one. could be more insider buying on the way. if there is i will post it
glta


<< Previous
Bullboard Posts
Next >>